Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1426 to 1440 of 1834 results for carers

  1. Pegaspargase for treating acute lymphoblastic leukaemia (TA408)

    Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia.

  2. Aflibercept for treating diabetic macular oedema (TA346)

    Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.

  3. Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)

    Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

  4. Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)

    NICE has developed a medtech innovation briefing (MIB) on Xpert GBS test for the intrapartum detection of group B streptococcus

  5. Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948)

    Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments.

  6. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA870)

    Evidence-based recommendations on ixazomib with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.

  7. Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132)

    This guideline covers diagnosing, assessing and managing primary hyperparathyroidism. It aims to improve recognition and treatment of this condition, reducing long-term complications and improving quality of life.

  8. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  9. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  10. Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

    Discontinued Reference number: GID-TA10711

  11. Pacritinib for treating myelofibrosis [ID880]

    Discontinued Reference number: GID-TA10133

  12. Depression in adults (QS8)

    This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.

  13. Service user experience in adult mental health services (QS14)

    This quality standard covers improving the experience of people using adult NHS mental health services. It describes high-quality care in priority areas for improvement.

  14. Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

    Discontinued Reference number: GID-TA10277

  15. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued Reference number: GID-TAG393